Related Experiment Video
Updated: Jun 12, 2026
06:13
Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults
Published on: December 1, 2023
Tight glucose control versus intermediate glucose control: a quasi-experimental study.
M S Durao1, A R Marra, D F Moura
1Intensive Care Unit, Hospital Israelita Albert Einstein, São Paulo, Brazil. marcelino@einstein.br
Anaesthesia and Intensive Care
|June 3, 2010
Summary
Intensive insulin treatment increases hypoglycemia risk. Intermediate glucose control (IGC) is safer than tight glucose control (TGC) in critically ill patients, reducing hypoglycemia and mortality risk.
Area of Science:
- Critical Care Medicine
- Endocrinology
- Metabolic Disorders
Background:
- Intensive insulin therapy in critically ill patients can elevate hypoglycemia risk.
- Balancing glycemic control and hypoglycemia is crucial for patient outcomes.
Purpose of the Study:
- To compare the safety and efficacy of tight glucose control (TGC) versus intermediate glucose control (IGC) in critically ill patients.
- To identify risk factors for hypoglycemia and mortality in this population.
Main Methods:
- A quasi-experimental study involving 130 critically ill patients.
- Patients were assigned to either TGC (4.4–6.1 mmol/l) or IGC (4.4–8.0 mmol/l) protocols.
- Analysis of hypoglycemia incidence, glycemic variability, and mortality risk factors.
Main Results:
- The IGC group maintained target glucose levels for longer (63% vs. 41%).
- Hypoglycemia (<3.3 mmol/l) was significantly lower in the IGC group (26.2% vs. 67.7%).
- Diabetes and TGC protocol were independent risk factors for hypoglycemia; mechanical ventilation, medical illness, and hypoglycemia were associated with mortality.
Conclusions:
- Tight glucose control (TGC) is challenging in intensive care units and significantly increases hypoglycemia incidence.
- Intermediate glucose control (IGC) is a safer strategy, associated with less hypoglycemia.
- Hypoglycemia (<3.3 mmol/l) is an independent predictor of in-hospital mortality.
Related Concept Videos
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:29Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...